AI주식인사이트AI Stock Insight
C

파로스아이바이오

388870KOSDAQ자연과학 및 공학 연구개발업

48.0 / 100

Reference Date: 2026-04-13

Financial Score9.0 / 40
News Sentiment20.0 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Slightly down 2.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Paros AI Bio is a R&D-focused company developing innovative drugs for rare and intractable diseases using its AI-based drug discovery platform, Chemiverse. Its lead pipeline, Lasmotinib (PHI-101), is an acute myeloid leukemia treatment designated as an orphan drug in the US, Korea, and Europe. The company also develops PHI-101-OC, a candidate for recurrent ovarian cancer. The platform enables faster drug development with reduced costs and higher success rates.

Number of Employees

33people

Average Salary

62.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
8.56Industry Average 3.820.0Point

2.2x industry avg (risky)

ROE
-66.12Industry Average -32.113.5Point

2.1x industry avg (excellent)

Debt Ratio
104.48Industry Average 7.520.0Point

13.9x industry avg (risky)

Trend 2023~20251.5 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
0.0 / 3

Avg ▼7.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -49.9% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Detailed Momentum

52-week position6.0Point

52w upper range (64%)

Current 9,210Won52-week high 11,62052-week low 4,745
1-month return2.0Point

1m -2.54% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
  • Neutral정기주주총회결과2026-03-27
  • Neutral본점소재지변경2026-03-27
  • Neutral사업보고서 (2025.12)2026-03-19
  • Neutral감사보고서제출2026-03-18